Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Aranesp Clear all

Conditions: Hypoxic Ischemic Encephalopathy
Interventions: Darbepoetin alfa, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: Up to 24 Hours
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Albuquerque, New Mexico • Nashville, Tennessee • Ogden, Utah + 3 more

Conditions: Spinal Ischemia, Stroke, Neuroprotection
Interventions: Darbepoetin alfa, Standard care; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 100 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Pancreas Cancer, Colorectal Cancer, Endometrial Cancer, Prostate Cancer
Interventions: Relational Agent (RA), Enhanced Usual Care (EUC); Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure
Interventions: Darbepoetin alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 2,278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 254
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 195 more

Conditions: Anemia of Chronic Kidney Disease
Interventions: Vadadustat, Erythropoiesis Stimulating Agent; Drug
Lead sponsor: USRC Kidney Research; Network
Eligibility: 18 Years and older
Enrollment: 2,116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Lone Tree, Colorado • Dalton, Georgia • Gallup, New Mexico + 2 more

Conditions: Prematurity
Interventions: Not listed
Lead sponsor: University of New Mexico; Other
Eligibility: 36 Months to 72 Months
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2020
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Salt Lake City, Utah

Conditions: Sarcoma
Interventions: Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), Adriamycin, Ifosfamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Blood Cancer, Myelodysplastic Syndromes, Myelodysplastic Syndromes (MDS)
Interventions: Darbepoetin alfa; Drug
Lead sponsor: Peter L Greenberg; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Anemia, Chronic Kidney Disease, Kidney Disease
Interventions: Darbepoetin Alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 42
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more

Conditions: Primary Care
Interventions: Relational Agent ( RA) Alex; Behavioral
Lead sponsor: Anita Y. Kinney, PhD, RN; Other
Eligibility: 18 Years to 70 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Anemia Associated With End Stage Renal Disease
Interventions: Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 26
States / cities: Anchorage, Alaska • Pine Bluff, Arkansas • Cerritos, California + 18 more

Conditions: CKD Anemia in Stable Dialysis Patients
Interventions: Epoetin Alfa, Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 74
States / cities: Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more

Conditions: Revised Medication Guide Formats
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Myelodysplastic Syndrome
Interventions: Erythropoietin, Cyclosporin A, G-CSF, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anemia, Cancer
Interventions: darbepoetin alfa; Biological
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Prostate Cancer, Anemia
Interventions: Aranesp; Drug
Lead sponsor: University of Washington; Other
Eligibility: Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Infant, Newborn
Interventions: Darbepoetin Alfa Injection, erythropoietin alfa injection, sham injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 1 Hour to 49 Hours
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 3
States / cities: Denver, Colorado • Ogden, Utah • Salt Lake City, Utah

Conditions: Anemia
Interventions: Peginesatide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 7 more

Conditions: Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
Interventions: darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 64
States / cities: Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more

Conditions: Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions: peginesatide, Darbepoetin alfa; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 68
States / cities: Montgomery, Alabama • Tempe, Arizona • Hot Springs, Arkansas + 62 more

Conditions: Anaemia, Aspergillosis, Allergic Bronchopulmonary
Interventions: Daprodustat, rhEPO, Placebo, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 126
States / cities: Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more

Conditions: Anemia Associated With Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa, Epoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 10
States / cities: Escondido, California • Denver, Colorado • Fort Lauderdale, Florida + 7 more

Conditions: Anemia
Interventions: darbepoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 22
States / cities: Los Angeles, California • Mather, California • Stanford, California + 18 more

Conditions: Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: darbepoetin alfa, epoetin alfa, fatigue assessment and management, quality-of-life assessment; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Darbe Administration in Newborns Undergoing Cooling for Encephalopathy

The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial

Choices About Genetic Testing And Learning Your Risk With Smart Technology

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Vafseo Outcomes In-Center Experience

Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin

Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

Project CARE: CAncer Risk Evaluation

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

Consumer Understanding and Use of Medication Guides

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.

Darbepoetin Administration to Preterm Infants

Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy